Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

Speciality: Oncology

Description:

Welcome to this informative session on the role of pazopanib in managing advanced renal cell carcinoma (RCC).

Renal cell carcinoma is among the most common kidney cancers in both men and women. The global burden is steadily rising due to changing lifestyle factors and improved diagnostic techniques. When RCC progresses to stage IV, or advanced RCC, it becomes difficult to cure. At this stage, treatment typically focuses on delaying disease progression, easing symptoms, and improving quality of life.

Recent years have brought promising developments in treating advanced RCC. One such advancement is the introduction of pazopanib, a targeted anti-cancer medication approved by the FDA. Pazopanib belongs to the tyrosine kinase inhibitor (TKI) class and works by blocking multiple proteins involved in tumor growth and angiogenesis, including VEGFRs, PDGFRs, and c-Kit.

By inhibiting these targets, pazopanib helps reduce tumor vascularization and limits cancer cell proliferation. Clinical trials, including the COMPARZ study, have shown that pazopanib is as effective as sunitinib in treating advanced RCC, with a distinct safety profile that makes it a suitable option for many patients.

In this session, you’ll gain insights into the mechanism of action, clinical efficacy, and adverse effect management of pazopanib. You’ll also learn about its role in treatment sequencing and emerging combination strategies in real-world oncology practice.

We encourage you to engage actively, as your participation enhances collective learning. Don’t forget to follow HiDoc for more such expert-led discussions, webinars, and updates on breakthrough therapies in oncology and beyond.

Let’s get started on this deep dive into pazopanib and its role in transforming care for patients with advanced RCC.

See More Webinars @ Hidoc Webinars